NO20055150L - Benzotiazolderivater som adenosin-reseptorligander - Google Patents

Benzotiazolderivater som adenosin-reseptorligander

Info

Publication number
NO20055150L
NO20055150L NO20055150A NO20055150A NO20055150L NO 20055150 L NO20055150 L NO 20055150L NO 20055150 A NO20055150 A NO 20055150A NO 20055150 A NO20055150 A NO 20055150A NO 20055150 L NO20055150 L NO 20055150L
Authority
NO
Norway
Prior art keywords
optionally substituted
lower alkyl
aza
halogen
alkyl
Prior art date
Application number
NO20055150A
Other languages
English (en)
Inventor
Roland Jakob-Roetne
Claus Riemer
Alexander Flohr
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20055150L publication Critical patent/NO20055150L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Oppfinnelsen angår forbindelser med den generelle formel hvor R1 er 1,4-dioksepanyl eller tetrahydropyran-4-yl; R2 er -N(R)-(CH2)n-5-eller 6-leddet ikke-aromatisk heterocyklisk gruppe, eventuelt substituert med én eller flere substituenter, valgt fra gruppen bestående av lavere alkyl eller-NR2, eller er -(CH2)n-5-eller 6 leddet ikke-aromatisk heterocyklisk gruppe, eventuelt substituert med -(CH2)n-OH, lavere alkyl, lavere alkoksy, eller er -CH2)n-5-eller 6-leddet aromatisk heterocyklisk gruppe, eventuelt substituert med lavere alkyl, lavere alkoksy, halogen, halogen-lavere alkyl, -CH2N(R)(CH2)2OCH3, -N(R)(CH2)2OCH3, -CH2-morfolinyl eller-CH2-pyrrolidinyl, eller er (CH2)n-cykloalkyl, eventuelt substituert med hydroksy eller er -N(R)-cykloalkyl, eventuelt substituert med hydroksy eller lavere alkyl, eller erfenyl, eventuelt substituert med lavere alkoksy, halogen, halogen-lavere-alkyl, lavere alkyl, -CH2-pyrrolidin-1-yl, -CH2-morfolinyl, -CH2N(R)(CH2)2OCH3 eller-CH2- N(R)C(O)-lavere alkyl, eller er 1,4-dioksa-8-aza-spiro[4.5]dekan, eller er2-oksa-5-aza-bicyklo[2.2.1]heptan, eller er 1-oksa-8-aza-spiro[4.5]dekan, eller er-N(R)-7-oksa-bicyklo[2.2.1]hept-2-yl eller er 2-aza-bicyklo[2.2.2]dekan; R er hydrogen eller lavere alkyl; n er 0 eller 1; og farmasøytisk akseptable syreaddisjonssalter derav for behandling av sykdommer, som angår A2A-reseptoren.
NO20055150A 2003-05-19 2005-11-03 Benzotiazolderivater som adenosin-reseptorligander NO20055150L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011039 2003-05-19
PCT/EP2004/005178 WO2005000842A1 (en) 2003-05-19 2004-05-14 Benzothiazole derivatives as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
NO20055150L true NO20055150L (no) 2005-11-04

Family

ID=33442729

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055150A NO20055150L (no) 2003-05-19 2005-11-03 Benzotiazolderivater som adenosin-reseptorligander

Country Status (28)

Country Link
US (1) US7371748B2 (no)
EP (1) EP1636223B1 (no)
JP (1) JP4444290B2 (no)
KR (1) KR100859886B1 (no)
CN (1) CN100528871C (no)
AR (1) AR044362A1 (no)
AT (1) ATE389652T1 (no)
AU (1) AU2004251814B2 (no)
BR (1) BRPI0410440A (no)
CA (1) CA2524366C (no)
CL (1) CL2004001067A1 (no)
CO (1) CO5630031A2 (no)
DE (1) DE602004012555T2 (no)
DK (1) DK1636223T3 (no)
ES (1) ES2301991T3 (no)
HK (1) HK1092469A1 (no)
HR (1) HRP20080207T3 (no)
IL (1) IL171686A (no)
MX (1) MXPA05012360A (no)
NO (1) NO20055150L (no)
NZ (1) NZ543074A (no)
PL (1) PL1636223T3 (no)
PT (1) PT1636223E (no)
RU (1) RU2351597C2 (no)
SI (1) SI1636223T1 (no)
TW (1) TW200505882A (no)
WO (1) WO2005000842A1 (no)
ZA (1) ZA200509294B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052930A2 (en) * 2006-11-03 2008-05-08 F. Hoffmann-La Roche Ag Preparation of 4-alk0xy-7- (tetrahydropyran-4-yl) benzothiazol-2-amine derivatives
SG11202000823WA (en) * 2017-08-01 2020-02-27 Merck Patent Gmbh Thiazolopyridine derivatives as adenosine receptor antagonists
AU2018320673B2 (en) * 2017-08-21 2023-03-30 Merck Patent Gmbh Benzimidazole derivatives as adenosine receptor antagonists
TW201920123A (zh) * 2017-08-21 2019-06-01 德商馬克專利公司 作為腺苷受體拮抗劑之喹㗁啉衍生物
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
JP2022505872A (ja) 2018-10-25 2022-01-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
ES2960883T3 (es) 2018-10-25 2024-03-07 Merck Patent Gmbh Derivados de 5-azaindazol como antagonistas de los receptores de adenosina
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100571161B1 (ko) * 2000-06-21 2006-04-17 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
CA2467825A1 (en) * 2001-11-27 2003-06-05 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
RU2334742C2 (ru) * 2003-01-13 2008-09-27 Ф.Хоффманн-Ля Рош Аг Производные бензоксазола и фармацевтическая композиция, обладающая свойствами лигандов рецептора аденозина

Also Published As

Publication number Publication date
BRPI0410440A (pt) 2006-06-06
AR044362A1 (es) 2005-09-07
ZA200509294B (en) 2006-10-25
US7371748B2 (en) 2008-05-13
RU2351597C2 (ru) 2009-04-10
HRP20080207T3 (en) 2008-06-30
ATE389652T1 (de) 2008-04-15
DE602004012555T2 (de) 2009-04-16
IL171686A (en) 2011-11-30
CL2004001067A1 (es) 2005-04-15
AU2004251814A1 (en) 2005-01-06
TW200505882A (en) 2005-02-16
PT1636223E (pt) 2008-05-06
ES2301991T3 (es) 2008-07-01
CN1791600A (zh) 2006-06-21
HK1092469A1 (en) 2007-02-09
EP1636223A1 (en) 2006-03-22
SI1636223T1 (sl) 2008-06-30
KR20060013406A (ko) 2006-02-09
JP2006528220A (ja) 2006-12-14
AU2004251814B2 (en) 2009-07-23
DK1636223T3 (da) 2008-06-23
CA2524366A1 (en) 2005-01-06
CO5630031A2 (es) 2006-04-28
KR100859886B1 (ko) 2008-09-23
MXPA05012360A (es) 2006-02-02
WO2005000842A1 (en) 2005-01-06
CA2524366C (en) 2012-03-13
DE602004012555D1 (de) 2008-04-30
JP4444290B2 (ja) 2010-03-31
EP1636223B1 (en) 2008-03-19
PL1636223T3 (pl) 2008-07-31
NZ543074A (en) 2009-01-31
US20040235915A1 (en) 2004-11-25
CN100528871C (zh) 2009-08-19
RU2005139527A (ru) 2006-07-27

Similar Documents

Publication Publication Date Title
NO20055150L (no) Benzotiazolderivater som adenosin-reseptorligander
NO20062370L (no) Amidderivater
MY140039A (en) Pyrido-(2,1-a)-isoquinoline derivatives as dpp-iv inhibitors
ES2584055T3 (es) Compuestos heterocíclicos de benzodioxol o benzodioxepina como inhibidores de la fosfodiesterasa
AR040806A1 (es) Derivados de piperidi-2-ona 1,6 disustituidos, composicion farmaceutica que la comprende y metodo de tratamiento
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
DK0944617T3 (da) Krystaller af benzimidazolderivater og deres fremstilling
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
YU48390B (sh) Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
AR037731A1 (es) Uso de ureas de benzotiazoles
AU2005288080A1 (en) Carbostyril compound
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ATE92485T1 (de) 3-(4-piperidin)-5-(2-sulphonylaminoethyl)-indol derivate.
NO20080871L (no) N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
JP2005538111A5 (no)
NO20083917L (no) Malonamidderivater som gammasekretaseinhibitorer
NO20055176L (no) Benzotiazolderivater og anvendelse derav i behandling av sykdommer vedrorende adenosin A2A-resepor
NO20054794L (no) 7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander
NO177138C (no) Analogifremgangsmåte ved fremstilling av substituerte imidazolderivater
NO20052360L (no) Forbedrede formuleringer inneholdende substituerte imidazolderivater
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
PT76123B (fr) Procede de preparation de nouveaux derives de benzadioxine
NO20065323L (no) 6-substituerte pyridoindolonderivater, fremstilling og anvendelse derav
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application